Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)

Keros Therapeutics' Non Operating Income history spans 7 years, with the latest figure at $273000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 101.59% year-over-year to $273000.0; the TTM value through Dec 2025 reached $6.6 million, up 197.35%, while the annual FY2025 figure was -$539000.0, 43.5% up from the prior year.
  • Non Operating Income reached $273000.0 in Q4 2025 per KROS's latest filing, up from -$253000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $9.3 million in Q4 2022 to a low of -$17.2 million in Q4 2024.
  • Average Non Operating Income over 5 years is $269050.0, with a median of -$62000.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: skyrocketed 12529.33% in 2022, then plummeted 280.23% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$75000.0 in 2021, then surged by 12529.33% to $9.3 million in 2022, then plummeted by 217.39% to -$10.9 million in 2023, then crashed by 57.23% to -$17.2 million in 2024, then surged by 101.59% to $273000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Non Operating Income are $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and $6.9 million (Q2 2025).